Loading…
Ken GriffinReduced
Citadel Advisors · Q2 2026
$7.03M
210.53K shares · 0.0% of portfolio
Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. (RARE) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Novato, United States and has 1,371 employees. The company is worth $1.57B. Revenue was $673M in fiscal 2025, up 20.2% from the year before. It reported a net loss of $575M. The share price is 60.0% below its 52-week high of $39.89. 5 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Cliff Asness (AQR Capital Management), at $214.14M. In that quarter, 2 of them opened or added to the position and 3 reduced it. Over the last 30 days, company insiders sold $107.9K of its stock on the open market and bought none.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -80.7% over 5Y.
today you would have $173.26▼ -82.7%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 12 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $23.00 | $42.07 | $47.82 | $46.33 | $84.09 | $138.43 | $42.71 | $43.48 | $46.38 | $70.31 | $112.18 | $43.88 | |
| P/S | 20.2x | 3.3x | 6.9x | 9.1x | 9.0x | 16.6x | 34.2x | 23.8x | 43.3x | 880.8x |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| AZTAAzenta, Inc. | $36.01 | — | 1.0x | 0.00% | -7.04% | $1.58B |
| GPCRStructure Therapeutics Inc. | $21.93 | — | 1.2x | 0.00% | -20.21% | $1.56B |
| NTLAIntellia Therapeutics, Inc. | $11.16 | — | 2.1x | 0.00% | -55.44% | $1.56B |
| GENBGenerate Biomedicines, Inc. | $12.09 |
| 22058.7x |
| — |
| — |
| P/B | 8.0x | — | 15.3x | 14.3x | 9.2x | 6.3x | 8.0x | 3.8x | 3.7x | 6.0x | 6.2x | 8.2x | 8.4x |
| EPS | -$5.83 | -$6.29 | -$8.25 | -$10.12 | -$6.70 | -$3.07 | -$7.12 | -$3.97 | -$7.12 | -$6.21 | -$3.96 | -$2.25 |
| Profit margin | -167.28% | -85.44% | -101.61% | -139.86% | -194.71% | -129.20% | -68.84% | -388.31% | -383.75% | -11567.34% | -184867.67% | — | — |
| ROE | -51.87% | — | -223.14% | -220.73% | -200.97% | -49.21% | -16.16% | -61.60% | -32.45% | -78.79% | -51.87% | -27.42% | -32.34% |
Median of the years shown; P/E years above 200x are left out.
| — |
| 3.4x |
| 0.00% |
| — |
| $1.55B |
| QUREuniQure N.V. | $23.11 | — | 4.9x | 0.00% | -157.61% | $1.6B |
| CERTCertara, Inc. | $10.09 | — | 1.6x | 0.00% | -2.21% | $1.54B |